Login to Your Account



Sage soars on phase III PPD data; expects filings next year for brexanolone

By Jennifer Boggs
Managing Editor

Friday, November 10, 2017

Sage Therapeutics Inc. scored a big win Thursday, disclosing positive top-line data from its pivotal program testing brexanolone in postpartum depression (PPD), results that should support regulatory filings next year and position the intravenously administered drug (previously known as SAGE-547) as potentially the first treatment specifically for PPD.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription